scholarly journals The Aggressiveness of African breast cancer: An expose’ on CD44+CD24-/low breast cancer stem cell

2021 ◽  
Author(s):  
Eric Gyan ◽  
Linda Ahenkorah-Fondjo ◽  
William K.B.A Owiredu ◽  
Andrew Jackson ◽  
Michael S. Toss ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Stem Cell ◽  
Poor Prognosis ◽  
Hormone Receptor Status ◽  
Clinicopathological Features ◽  
Mitotic Count ◽  
Inverse Association ◽  
Tumour Grade ◽  
The Individual ◽  
The Relationship

Abstract Breast cancer (BC) in Africans and people of African descent is generally aggressive, with poorer prognosis and worse clinical outcomes. The molecular basis of this is however not entirely understood. The CD44+ / CD24-/low BC stem cell is known for its tumourigenic potential, tumour aggressiveness and its association with poor prognosis. This study identifies the relationship between CD44+/ CD24-/low BC stem cells and clinicopathological features of breast cancer in an African population.Methodology A Ghanaian BC cohort (n= 222) was used to assess CD44 and CD24 expression. Tissue microarray was constructed from the cohort samples and Immunohistochemically stained with CD44 and CD24 antibodies. The associations between clinicopathological features and the expression of the individual markers and their combinations were analysed. Results Of the total 222 breast cancer samples, 81.9 % were cytoplasmic CD24 positive and were associated with higher tumour grade (OR-3.623; r=0.199; p=0.004), gender (OR-9.514; p=0.028), clinical prognostic grading (OR-2.357 r= 0.162; p=0.027) and Her2 positivity (OR-0.216; r=-0.155; p=0.026). CD44 was associated with higher tumour grade (OR-3.148; r= 0.145; p-0.037), and increased mitotic count (OR-3.043, r= 0.173; p=0.028). There was no association between CD44 expression and hormone receptor status. Together, CD44+/CD24-/low staining was associated with higher tumour grade (OR-3.162; r=0.166; p=0.018), gender (OR- 12.0; p=0.012), and higher clinical prognostic staging (OR- 2.888; r=0.186; p=0.011). An inverse association of CD44+CD24+ was found with tumour grade (OR-0.220; r=-0.246; p=0.000), mitotic count (OR-0.406; r=-0.190; p=0.017) and clinical prognostic staging (OR-0.486; r=-0.151; p=0.040). There was no association between CD44-CD24+ and all the clinicopathological features.Conclusion Combined, CD44+CD24-/low was associated with poor prognosis and tumour aggression and may contribute to the tumour aggressiveness of African breast cancer. CD24 expression as a stand-alone marker was found to correlate with clinical and pathological indicators of tumour aggressiveness and poor prognosis.

scholarly journals Increased claudin-4 expression is associated with poor prognosis and high tumour grade in breast cancer

2009 ◽  
Vol 124 (9) ◽  
pp. 2088-2097 ◽  
Author(s):  
Fiona Lanigan ◽  
Eadaoin McKiernan ◽  
Donal J. Brennan ◽  
Shauna Hegarty ◽  
Robert C. Millikan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Poor Prognosis ◽  
Tumour Grade

scholarly journals High JAK2 Protein Expression Predicts a Poor Prognosis in Patients with Resectable Pancreatic Ductal Adenocarcinoma

2020 ◽  
Vol 2020 ◽  
pp. 1-8
Author(s):  
Yang Song ◽  
Mei-Yue Tang ◽  
Wei Chen ◽  
Zhe Wang ◽  
Si-Liang Wang
Keyword(s):  
Protein Expression ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Poor Prognosis ◽  
Prognostic Value ◽  
Survival Curve ◽  
Clinicopathological Features ◽  
Ductal Adenocarcinoma ◽  
Clinicopathological Analysis ◽  
Primary Focus ◽  
The Relationship

Background. Pancreatic ductal adenocarcinoma (PDAC) is one of the most fatal malignancies worldwide. The JAK/STAT signaling pathway is involved in pancreatic cancer tumorigenesis. However, the prognostic value of JAK2 expression in resectable PDAC is unclear. Method. In this study, we performed a clinicopathological analysis of 62 resectable PDAC cases with a primary focus on survival. JAK2 expression was examined by immunohistochemistry. The relationship between JAK2 expression and clinicopathological features and prognosis was analyzed. Results. Survival curve analyses revealed that high levels of JAK2 expression predict a poor prognosis in resectable PDAC patients. Multivariate analysis confirmed that JAK2 expression can predict the prognosis of PDAC. Conclusions. Assessment of JAK2 protein expression may be a promising method to predict prognosis in patients with resectable PDAC.

scholarly journals High Expression of Complement Component C7 Indicates Poor Prognosis of Breast Cancer and Is Insensitive to Taxane-Anthracycline Chemotherapy

2021 ◽  
Vol 11 ◽  
Author(s):  
Huikun Zhang ◽  
Yawen Zhao ◽  
Xiaoli Liu ◽  
Li Fu ◽  
Feng Gu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Cancer Patients ◽  
Poor Prognosis ◽  
Triple Negative ◽  
Ductal Carcinoma ◽  
High Expression ◽  
Breast Cancer Patients ◽  
The Relationship ◽  
Triple Negative Subtype

BackgroundBreast cancer is the most commonly diagnosed cancer worldwide. However, the well-known biomarkers are not enough to meet the needs of precision medicine. Novel targets are desirable and highly valuable for improved patient survival. In this regard, we identified complement component C7 as one of the candidates based on data from the OCOMINE database.MethodsC7 expression was examined by immunohistochemistry in 331 cases of invasive ductal carcinoma (IDC), 45 cases of ductal carcinoma in situ (DCIS), and 52 cases of non-neoplastic tissues adjacent to tumor. Then, C7 expression was further confirmed by Western blot analysis based on IDC specimens and non-neoplastic breast specimens. The relationship between the C7 expression and prognosis of breast cancer patients was analyzed in order to investigate the function of C7 in breast cancer patients. Meanwhile, we also analyzed the relationship between the C7 expression and prognosis of 149 patients treated with conventional TE (taxane and anthracycline)-based chemotherapy. Then, a cohort of patients (22 cases) treated with TE neoadjuvant chemotherapy was used to further confirm the relationship between the C7 expression and TE-based chemosensitivity.ResultsIn our present study, we reported for the first time that C7 was an independent prognostic factor of breast cancer and C7 expression of IDC tissues was higher than non-neoplastic tissues adjacent to tumor and DCIS. In a cohort of 331 IDC patients, high expression of C7 indicated poor prognosis especially in the triple negative subtype and luminal B subtype. Furthermore, C7 was also a promoting factor for triple negative subtype patients to develop bone metastasis. Meanwhile, we provided the first evidence that patients with high C7 expression were insensitive to TE (taxane and anthracycline)-based chemotherapy by analyzing a cohort of 149 patients treated with TE-based chemotherapy and another cohort of 22 patients treated with TE neoadjuvant chemotherapy.ConclusionsIn summary, high expression of C7 may promote breast cancer development and might be insensitive to TE-based chemotherapy. Our present study laid a foundation to help clinicians improve the identification of patients for TE-based chemotherapy by C7 in the era of precision medicine.

scholarly journals DEAD-box helicase 27 enhances stem cell-like properties with poor prognosis in breast cancer

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Shan Li ◽  
Jinfei Ma ◽  
Ang Zheng ◽  
Xinyue Song ◽  
Si Chen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Stem Cell ◽  
Western Blot ◽  
Cancer Cells ◽  
Normal Tissue ◽  
Poor Prognosis ◽  
Breast Cancer Cells ◽  
Breast Cancer Prognosis ◽  
Cancer Prognosis ◽  
Dead Box

Abstract Background Although the rapid development of diagnosis and treatment has improved prognosis in early breast cancer, challenges from different therapeutic response remain due to breast cancer heterogeneity. DEAD-box helicase 27 (DDX27) had been proved to influence ribosome biogenesis and identified as a promoter in gastric and colorectal cancer associated with stem cell-like properties, while the impact of DDX27 on breast cancer prognosis and biological functions is unclear. We aimed to explore the influence of DDX27 on stem cell-like properties and prognosis in breast cancer. Methods The expression of DDX27 was evaluated in 24 pairs of fresh breast cancer and normal tissue by western blot. We conducted Immunohistochemical (IHC) staining in paraffin sections of 165 breast cancer patients to analyze the expression of DDX27 and its correlation to stemness biomarker. The Cancer Genome Atlas-Breast Cancer (TCGA-BRCA) database and the Clinical Proteomic Tumor Analysis Consortium (CPTAC) database were used to analyze the expression of DDX27 in breast cancer. Kaplan–Meier survival analysis were used to investigate the implication of DDX27 on breast cancer prognosis. Western blot, CCK-8 assay, Transwell assay and wound-healing assay were carried out to clarify the regulation of DDX27 on stem cell-like properties in breast cancer cells. Gene Set Enrichment Analysis (GSEA) was performed to analyze the potential molecular mechanisms of DDX27 in breast cancer. Results DDX27 was significantly high expressed in breast cancer compared with normal tissue. High expression of DDX27 was related to larger tumor size (p = 0.0005), positive lymph nodes (p = 0.0008), higher histological grade (p = 0.0040), higher ki-67 (p = 0.0063) and later TNM stage (p < 0.0001). Patients with high DDX27 expression turned out a worse prognosis on overall survival (OS, p = 0.0087) and disease-free survival (DFS, p = 0.0235). Overexpression of DDX27 could enhance the expression of biomarkers related to stemness and promote stem cell-like activities such as proliferation and migration in breast cancer cells. Conclusion DDX27 can enhance stem cell-like properties and cause poor prognosis in breast cancer, also may be expected to become a potential biomarker for breast cancer therapy.

scholarly journals CD5 and CD43 expression are associate with poor prognosis in DLBCL patients

Open Medicine ◽  
2018 ◽  
Vol 13 (1) ◽  
pp. 605-609 ◽  
Author(s):  
Hui Huang ◽  
Zhandong Li ◽  
Chuansheng Huang ◽  
Jun Rao ◽  
Qin Xie ◽  
...  
Keyword(s):  
Poor Prognosis ◽  
Cell Lymphoma ◽  
Clinical Stage ◽  
B Cell Lymphoma ◽  
Clinicopathological Features ◽  
Large B Cell Lymphoma ◽  
B Virus ◽  
Immuno Histochemistry ◽  
The Relationship ◽  
Large B Cell

AbstractObjectiveTo investigate the expression and clinical significance of CD5 and CD43 in diffuse large B cell lymphoma (DLBCL) (unspecified).MethodsSixty - five patients with diagnosed DLBCL were enrolled. The expressions of CD5, CD43, CD10, Bcl-6 and Mun-1 were detected by immuno histochemistry. The relationship between CD5 and CD43 and clinicopathological features and prognosis of DLBCL was analyzed.ResultsIn sixty - five adult DLBCL patients , 6 cases of DLBCL (9.2%) were CD5 positive, 24 cases of DLBCL (36.9%) were CD43 positive, 5 cases of DLBCL (7.7%) were both CD5 and CD43 positive. 40 cases of DLBCL (61.5%) were CD5 and CD43 negative. CD5 expression was not related to age, sex, clinical stage, type of immunophenotype (Hans typing), location, and whether infected with hepatitis B virus (HBV); CD43 expression was correlated with immunophenotyping and HBV i nfection, but was not correlated with the age, sex, clinical stage, and site. Median survival time was significantly lower in CD5- and CD43- positive DLBCL patients than CD5- and CD43-negative patien ts.ConclusionThe prognosis of DLBCL patients may be worse with positive CD5 and CD43 expression.

CD24 expression and breast cancer stem cell phenotype

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 11106-11106
Author(s):  
G. Rappa ◽  
F. Anzanello ◽  
A. Lorico
Keyword(s):  
Breast Cancer ◽  
Stem Cell ◽  
Breast Carcinoma ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Carcinoma Cells ◽  
Cell Phenotype ◽  
Cell Cycle Distribution ◽  
Breast Carcinoma Cells ◽  
The Relationship

11106 Background: Several studies suggest the existence of breast cancer-initiating cells (BCIC), responsible for tumor development and progression. Initial reports that only the CD44+CD24−/low subpopulation contains BCIC have been challenged by subsequent studies. We examined the relationship between CD24 and biological properties of breast cancer cells. Methods: MA-11 breast carcinoma cells, originating from bone marrow micrometastases, are CD44+ and have an heterogeneous expression of CD24 (214,000/cell; range 0–1,120,000). We have previously reported that upon in vitro culture as mammospheres under stem cell-like conditions, MA-11 cells acquired increased tumorigenicity and a CD44+CD24−/low phenotype. We have now investigated the relationship between CD24 expression and tumorigenicity in the MA-11 model. Results: Upon passage of MA-11 mammospheres in adherent culture, cells rapidly re-expressed CD 24. The rapid increase in CD24 was consistent with antigen up-regulation, not selection of CD24−/low cells. Exposure of adherent MA-11 cells to imatinib for 72h resulted in a reversible decrease in CD24 from 214,000 to 15,800/cell. CD44+CD24−/low cells, sorted by flow cytometry, generated CD44+CD24high, and CD44+CD24highgenerated CD44+CD24−/low. Immediately after sorting, >90% CD44+CD24−/low cells were in G0/G1. After 24–48 h in culture, cell cycle distribution, growth rate and invasiveness of the sorted cell populations were equivalent. Upon injection and s.c. growth, CD24 expression of CD44+CD24−/low populations and clones increased from 10,000 to 220,000/cell. Similarly, CD44+CD24−/low clones derived from human MCF-7 breast carcinoma cells formed tumors containing >99% CD44+CD24high cells. The average number of CD24 per cell was equivalent for tumors formed upon injection of CD44+CD24−/low, CD44+CD24+, mammosphere-derived cells or parental adherent MA-11 cells. The tumorigenic potentials of sorted CD44+CD24−/low, CD44+CD24−/lowsub-populations and clones in nu/nu mice were equivalent. Conclusions: CD44+CD24−/low breast cancer cells are not associated with increased tumorigenicity; the high CD24 level of mouse xenografts derived from both CD44+CD24−/low and CD44+CD24hi breast cancer cells suggests an important role for CD24 in tumor growth. No significant financial relationships to disclose.

Abstract 2273: Validation of putative stem cell factor SOX2 as predictive marker in breast cancer – with overall poor prognosis

2011 ◽  
Author(s):  
Leon Paul Pradel ◽  
Stefan Swierczynski ◽  
Richard Greil ◽  
Otto Dietze ◽  
Cornelia Hauser-Kronberger
Keyword(s):  
Breast Cancer ◽  
Stem Cell ◽  
Stem Cell Factor ◽  
Poor Prognosis ◽  
Predictive Marker ◽  
Putative Stem Cell

scholarly journals LINC01087 indicates a poor prognosis of glioma patients with preoperative MRI

2021 ◽  
Author(s):  
Wangsheng Chen ◽  
Fei Wang ◽  
Jianhua Zhang ◽  
Changqing Li ◽  
Lan Hong
Keyword(s):  
Breast Cancer ◽  
Poor Prognosis ◽  
Prognostic Value ◽  
Prognostic Significance ◽  
Glioma Cells ◽  
Cancer Tissue ◽  
Non Coding Rna ◽  
Mri Diagnosis ◽  
The Relationship ◽  
U251 Cells

AbstractLong intergenic non-coding RNA 01,087 (LINC01087) has been concerned as an oncogene in breast cancer, while its mechanism in glioma has been little surveyed. Thus, we searched the prognostic value and functional action of LINC01087 in glioma. Glioma patients after preoperative MRI diagnosis were enrolled, and LINC01087, microRNA (miR)-1277-5p, and alkaline ceramidase 3 (ACER3) levels were tested in glioma cancer tissue. The correlation between LINC01087 expression and the survival of patients were analyzed. LINC01087, miR-1277-5p, and ACER3 levels in U251 cells were altered via transfection, and cell malignant phenotypes were monitored. The relationship between miR-1277-5p and LINC01087 or ACER3 was detected. The LINC01087 and ACER3 expression was in up-regulation and the miR-1277-5p expression was in down-regulation in clinical glioma samples. High expression of LINC01087 was associated with poor prognosis of glioma patients with preoperative MRI. LINC01087 silencing restrained tumor malignancy in glioma cells. Mechanistically, LINC01087 directly interacted with miR-1277-5p. ACER3 was a known target of miR-1277-5p. Moreover, rescue assays reveal that miR-1277-5p overexpression (or ACER3 overexpression) reversed the effects of LINC01087 upregulation (or miR-1277-5p upregulation) on glioma cells. LINC01087 has prognostic significance in glioma and silencing LINC01087 deters glioma development through elevating miR-1277-5p to reduce ACER3 expression.

Sign in / Sign up

Export Citation Format

Share Document